| CAT # | Product Name | Description |
| CPD1805 | IACS-010759; IACS-010759 (HCl) | IACS-010759 or IACS-10759 is a potent and selective Oxidative Phosphorylation Inhibitor (IC50 < 10 nM) with potential antineoplastic activity. |
| CPDD2004 | CU CPT 9a | CU-CPT-9a is a specific antagonist of TLR8. |
| CPD1221 | Revefenacin; TD 4208; GSK1160724; Yupelri | Revefenacin (TD-4208; GSK1160724) is a potent mAChR antagonist; has a high affinity on M3 receptor with a Ki of 0.18 nM |
| CPD2807 | BAY 293 | BAY-293 is a potent SOS1 inhibitor that blocks RAS activation via disruption of the RAS-SOS1 interaction. BAY-293) selectively inhibits the KRAS-SOS1 interaction with an IC50 of 21 nM and is a valuable chemical probe for future investigations. |
| CPD1213 | Elimusertib; BAY 1895344 | BAY-1895344 is a selective ATR (ataxia-telangiectasia and Rad3 related protein) inhibitor that inhibits proliferation of a broad spectrum of human tumor cell lines (median IC50 = 78 nM). |
| CPD1841 | Resmetirom; MGL3196; VIA 3196 | Resmetirom, or MGL-3196, shows outstanding safety in a rat heart model and is efficacious in a preclinical model at doses that showed no impact on the central thyroid axis. |
| CPD1212 | Avapritinib; BLU 285 | BLU-285 is a potent and selective exon 17 mutant KIT kinase inhibitor with IC50 of 0.27 nM for KIT D816V. |
| CPDD1230 | Verucerfont; GSK 561679; GSK 561679A; NBI 77860 | Verucerfont, also known as GSK561679 and NBI77860, is a CRF-1 antagonist. Verucerfont blocks the CRH-1 receptor, and so reduces ACTH release following chronic stress. |
| CPDD1633 | Adavivint; SM 04690; LORECIVIVINT | A novel small molecule Wnt pathway inhibitor with EC50 of 3 nM in vitro; induces hMSC differentiation into mature, functional chondrocytes and decreases cartilage catabolic marker levels; significantly improves Osteoarthritis Research Society International (OARSI) histology scores and biomarkers in a rodent OA model. |
| CPDD1644 | Rilzabrutinib; PRN1008 | PRN1008 is a potent, selective and reversible covalent inhibitor of BTK ((IC50 = 1.3 ± 0.5 nM).) with extended PD effects in vivo. |
| CPD1017 | Bardoxolone; CDDO; RTA 401 | Bardoxolone is a novel nuclear regulator factor (Nrf-2) activator. |
| CPD1542 | Palupiprant; E-7046; ER-886046 | E7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM, exhibiting anti-tumor activities. |
| CPDB0053 | AZD4547 | AZD 4547 is a selective inhibitor of the fibroblast growth factor receptor (FGFR) tyrosine kinase with IC50 values of 0.2, 2.5, and 1.8 nM for FGFR1, 2, and 3, respectively. |
| CPD112243 | CCR2 antagonist 3 | CCR2 antagonist 3 is an antagonist of chemokine receptor 2 (CCR2). |
| CPD108542 | Tirabrutinib; ONO-4059 | Tirabrutinib (ONO-4059) is an orally effective, highly selective Bruton's Tyrosine Kinase (BTK) inhibitor. |
| CPD110808 | RMC 0331; RM 023 | RMC-0331 (RM-023) is a highly efficient, selective, and orally bioavailable SOS1 inhibitor. |
| CPD1599 | CDDO-3-P-Im; CDDO-2P-Im | CDDO-2P Im is a CDDO imidazole amine analogue with chemopreventive properties. |
| CPDB1593 | Telaglenastat; CB-839 | CB-839 an is orally bioavailable inhibitor of glutaminase, with potential antineoplastic activity. |
| CPD1598 | CDDO Imidazolide; CDDO Im; RTA 403; TP 235 | CDDO Im (RTA-403) is an activator of Nrf2 and PPAR. |
| CPD114656 | (R)-Pirtobrutinib | (R) Pirtobrutinib is a less active isomer of Pirtobrutinib. Pirtobrutinib is a highly selective and non covalent next-generation BTK inhibitor. |
| CPD2500 | Olutasidenib; FT-2102 | Olutasidenib is a potent, selective inhibitor of mutant Isocitrate dehydrogenase (IDH)1 for the treatment of acute myeloid leukemia |
| CPD9951 | Batefenterol；GSK 961081; TD-5959 | Batefenterol is a muscarinic antagonist and β2-adrenergic receptor (β2-AR) agonist (Kis = 1.4, 1.3, and 3.7 nM, for hM2, hM3, and hβ2-AR, respectively in a radioligand binding assay). |
| CPD3619 | RTA dh404；CDDO-dhTFEA | |
| CPD3236 | methyl (4aS,6aR,6bR,8aR,12aR,12bR,14aR,14bS)-11... | |
| CPD115153 | NX-2127；zelebrudomidum; zelebrudomide | NX-2127 is an orally effective BTK inhibitor. |
| CPDD0995 | Bardoxolone methyl; CDDO Methyl ester; CDDOMe; ... | The synthetic oleanane triterpenoid CDDO (Item No. 81035) is a Nrf2 activator that inhibits proliferation and induces differentiation and apoptosis in various cancer cells. |
| CPD0854 | Sotagliflozin; LX 4211 | Sotagliflozin (LX-4211) is an SGLT1/2 inhibitor and an anti diabetes agent. |
| CPD1111 | MAK683; EED inhibitor 1 | MAK683 is an inhibitor of embryonic ectoderm development (EED) |
| CPD107768 | Icotinib HCl；BPI2009 | Icotinib Hydrochloride (BPI-2009) is an effective and selective EGFR inhibitor |
| CPD2809 | AMG-510 | AMG-510 is a potent KRAS G12C covalent inhibitor. AMG-510 selectively targets the KRAS p.G12C mutant, at either the DNA, RNA or protein level, and prevents, through an as of yet not elucidated manner, expression of and/or tumor cell signaling through the KRAS p.G12C mutant. This may inhibit growth in KRAS p.G12C-expressing tumor cells |